Mon, Nov 24, 2014, 3:33 PM EST - U.S. Markets close in 27 mins.


% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • pylesm pylesm Aug 21, 2013 1:23 AM Flag

    Mannkind vis a vis Gilead

    Does anyone else see an analogy here? Gilead put a huge amount of effort to get the first once daily HIV pill on the market. Even I was really skeptical, thinking what's the difference; one pill or three, when you can take the three pills just once daily. However, I was wrong. Atripla launched Gilead into the big leagues.

    Seems AfrezzaUser has been steadfast in pointing out the lifestyle advantages; primarily of simply being able to eat a meal without being concerned about timing your mealtime insulin. Having to time every meal, every day, seems to be a HUGE pain.

    If there's any comparison here, it would be Afrezza offers a lot more lifestyle advantages to diabetics than Atripla did to HIV patients. And note the rapid growth in market share for Atripla after it launched, even though it carried a premium price.

    Seems like patients might end up being the driving force along with some really good DTC advertising to get the word out.

6.165-0.015(-0.24%)3:33 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.